ArrayExpress Uploader0humannot knownprimary721752malepoorprimary56269malenot knownnot known32KCL-22femalepoornot knownNot availablePC-3Mmalepoornot known11Rajimalenot knownnot known62NCI-H929femalenot knownprimary51486femalenot knownmetastasis22276malenot knownprimary55698malenot knownnot known59KG-1malepoorprimary60251malemoderateprimary7094malenot knownnot known73JURL-MK1malegoodmetastasis70546malepoormetastasis63289malepoormetastasis58526malepoornot knownNot availableNCI-H460malepoorprimary19MOLT-4malenot knownnot known11Saos-2femalepoorprimary561121femalepoorrecurrent431781malenot knownmetastasis41520malenot knownmetastasis351341femalenot knownnot known60NIH:OVCAR-3femalenot knownprimary741183malepoornot known53K-562femalepoornot known69MCF-7femalenot knownnot known81T-24femalepoornot knownNot availableIM-9femalenot knownmetastasis63462malenot knownnot known24PL-21malepoornot knownNot availableRKONot availablegoodmetastasis51401femalepoornot knownNot availableHCT-116malepoornot known51MDA-MB-231femalepoornot known14Jurkatmalegoodprimary76899femalenot knownnot known56lp-1femalepoornot known36HL-60femalepoornot known44HT-29femalemoderatemetastasis601657femalegoodprimary66575malenot knownprimary55MEG-01malepoornot knownNot available22Rv1malepoornot known69DU-145malenot knownnot known56CAL-27malepoornot known37U-937malenot knownnot known7TE671femalenot knownprimary5EM-2femalepoormetastasis661138femalepoormetastasis521352malepoorrecurrent731118femalepoormetastasisNot available1218femalenot knownnot known31NOMO-1femalegoodnot known53HUT-78malenot knownnot known56PANC-1malenot knownnot known10MV4-11malepoormetastasis551103malenot knownmetastasis601792malepoornot known61RPMI8226malenot knownnot known65OCI-AML2malepoornot known50LNCAPmalepoorprimary59629malepoornot known36L-363femalepoorprimary54393malepoorprimary633011malegoodmetastasis46DiFifemalepoorprimary34529femalepoormetastasis59983maleundifferentiatednot known57JHH-6femalenot knownnot known51JHH-4malenot knownnot known57JHH-2malepoornot known38OCUM-1femalepoormetastasis35NUGC-4femalepoornot known62MKN45femalemoderatenot known63IM95malepoornot known66Fu97femalenot knownnot known54SNU-878femalenot knownnot known49SNU-761malenot knownnot known52SNU-739malenot knownnot known43SNU-475malenot knownnot known52SNU-449malenot knownnot known40SNU-423maleundifferentiatednot known68HLEmalenot knownnot known4CCRF-CEM-VCRfemalenot knownnot knownNot availableSNU-899Not availablenot knownnot knownNot availableSNU-1076Not availablepoornot known62498malepoornot known4CCRF-CEMfemalenot knownnot known72MKN1malegoodnot known39MKN7male2246arrayexpress_sid4Background: Antimalarials have anticancer potential. Results: We have systematically tested five distinct antimalaria drugs in a panel...E-GEOD-51739/profile/8773/arrayexpressuploader591cancercellmalariaDec.12, 2014Falseanticancer-properties-of-distinct-antimalaria-drugE-GEOD-51739_A-AFFY-44Anticancer properties of distinct antimalaria drug classesJul.11, 2014Background: Antimalarials have anticancer potential. Results: We have systematically tested five distinct antimalaria drugs in a panel of cancer cell lines. Conclusion: Three antimalarial classes display potent antiproliferative activity, and their potency is correlated with cancer cell gene expression patterns. Significance: We confirm and extend anticancer potential of these antimalarials and we discuss their therapeutic potential based on clinical data. Key words: Malaria, Anticancer drug, Drug Discovery, Genomics, Gene Expression, Bioinformatics, Cancer Affymetrix® HG-U133 Plus 2.0 mRNA expression arrays were used to determine the expression. CEL result files were pre-processed using the RMA (Irizarry et al, 2003) algorithm. This microarray analysis was performed for 91 cell lines.http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-51739http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-51739/samples/